Abstract

Clinical Evaluation of Nitrofurantoin in Patients of Acute Lower Urinary Tract Infection

Highlights

  • Bansal N, et al Int J Pharm PharmacolUrinary Tract Infection (UTI) is one of the most common bacterial infections and second most common infectious disease in the community practice [1]

  • The agents most commonly used for the treatment of uncomplicated UTIs include the combination drug trimethoprim and sulfamethoxazole, trimethoprim, β lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine

  • Nitrofurantoin has traditionally been prescribed as 7-day regimen, similar microbiological and clinical efficacies are noted with a 5-day course

Read more

Summary

Introduction

Bansal N, et al Int J Pharm PharmacolUrinary Tract Infection (UTI) is one of the most common bacterial infections and second most common infectious disease in the community practice [1]. All the age groups from children to geriatric are affected It is one of the common cause of morbidity in both outpatient as well as hospitalized patients. The agents most commonly used for the treatment of uncomplicated UTIs include the combination drug trimethoprim and sulfamethoxazole, trimethoprim, β lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine. These agents are preferred because of their safety, spectrum of activity against suspected uropathogens, and favorite pharmacokinetic profiles. Resistance to nitrofurantoin remains low despite >60 years of use Since this drug affects bacterial metabolism in multiple pathways, several mutational steps are required for the development of resistance. Nitrofurantoin has gained importance recently because it has retained activity against a useful proportion of urinary tract coliforms that have acquired resistance to trimethoprim, oral β lactams and quinolones [12]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.